Adding Bismuth to Rabeprazole-Based First-Line Triple Therapy Does Not Improve the Eradication of Helicobacter pylori
This randomized controlled study aimed to evaluate whether adding bismuth to the standard first-line triple therapy could improve the eradication rate of Helicobacter pylori. A total of 162 patients with Helicobacter pylori infection were randomly assigned to either the 7-day triple therapy group (R...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2017/5320180 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832550210295824384 |
|---|---|
| author | Meng-Chieh Wu Yao-Kuang Wang Chung-Jung Liu Fang-Jung Yu Fu-Chen Kuo Min-Li Liu Chao-Hung Kuo Deng-Chyang Wu Yao-Kang Huang I-Chen Wu |
| author_facet | Meng-Chieh Wu Yao-Kuang Wang Chung-Jung Liu Fang-Jung Yu Fu-Chen Kuo Min-Li Liu Chao-Hung Kuo Deng-Chyang Wu Yao-Kang Huang I-Chen Wu |
| author_sort | Meng-Chieh Wu |
| collection | DOAJ |
| description | This randomized controlled study aimed to evaluate whether adding bismuth to the standard first-line triple therapy could improve the eradication rate of Helicobacter pylori. A total of 162 patients with Helicobacter pylori infection were randomly assigned to either the 7-day triple therapy group (RAK regimen: rabeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg bid; n=81) or the bismuth plus triple therapy group (n=81). In the RBAK group, bismuth subcitrate 360 mg twice daily was added to the RAK regimen. A follow-up endoscopy or urea breath test was performed at least 4 weeks after eradication to confirm the treatment efficacy. Comparable compliance and Helicobacter pylori eradication rates were observed in both groups in either intention-to-treat [RAK 72.8% (59/81) versus RBAK 77.8% (63/81); p=0.47] or per protocol analysis [RAK 74.7% (59/79) versus RBAK 81.8% (63/77); p=0.26]. Adverse effects were commonly reported (50.6% for both groups) although most of these did not cause cessation of treatment. The resistance rate was 27.2% for metronidazole and 12.3% for clarithromycin. Adding bismuth to the standard 7-day triple therapy did not substantially increase the eradication rate. Further study is needed clarifying whether extending the duration of RBAK regimen to 10–14 days can lead to a better result. |
| format | Article |
| id | doaj-art-4a8e3a01f8cc4dc0b5149830e247d6dd |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-4a8e3a01f8cc4dc0b5149830e247d6dd2025-02-03T06:07:26ZengWileyGastroenterology Research and Practice1687-61211687-630X2017-01-01201710.1155/2017/53201805320180Adding Bismuth to Rabeprazole-Based First-Line Triple Therapy Does Not Improve the Eradication of Helicobacter pyloriMeng-Chieh Wu0Yao-Kuang Wang1Chung-Jung Liu2Fang-Jung Yu3Fu-Chen Kuo4Min-Li Liu5Chao-Hung Kuo6Deng-Chyang Wu7Yao-Kang Huang8I-Chen Wu9Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, TaiwanSchool of Medicine, College of Medicine, E-Da Hospital, I-Shou University, Kaohsiung, TaiwanDepartment of Pharmacy, E-Da Cancer Hospital, Kaohsiung, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Ten-Chan General Hospital, Chung-Li, Taoyuan, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, TaiwanThis randomized controlled study aimed to evaluate whether adding bismuth to the standard first-line triple therapy could improve the eradication rate of Helicobacter pylori. A total of 162 patients with Helicobacter pylori infection were randomly assigned to either the 7-day triple therapy group (RAK regimen: rabeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg bid; n=81) or the bismuth plus triple therapy group (n=81). In the RBAK group, bismuth subcitrate 360 mg twice daily was added to the RAK regimen. A follow-up endoscopy or urea breath test was performed at least 4 weeks after eradication to confirm the treatment efficacy. Comparable compliance and Helicobacter pylori eradication rates were observed in both groups in either intention-to-treat [RAK 72.8% (59/81) versus RBAK 77.8% (63/81); p=0.47] or per protocol analysis [RAK 74.7% (59/79) versus RBAK 81.8% (63/77); p=0.26]. Adverse effects were commonly reported (50.6% for both groups) although most of these did not cause cessation of treatment. The resistance rate was 27.2% for metronidazole and 12.3% for clarithromycin. Adding bismuth to the standard 7-day triple therapy did not substantially increase the eradication rate. Further study is needed clarifying whether extending the duration of RBAK regimen to 10–14 days can lead to a better result.http://dx.doi.org/10.1155/2017/5320180 |
| spellingShingle | Meng-Chieh Wu Yao-Kuang Wang Chung-Jung Liu Fang-Jung Yu Fu-Chen Kuo Min-Li Liu Chao-Hung Kuo Deng-Chyang Wu Yao-Kang Huang I-Chen Wu Adding Bismuth to Rabeprazole-Based First-Line Triple Therapy Does Not Improve the Eradication of Helicobacter pylori Gastroenterology Research and Practice |
| title | Adding Bismuth to Rabeprazole-Based First-Line Triple Therapy Does Not Improve the Eradication of Helicobacter pylori |
| title_full | Adding Bismuth to Rabeprazole-Based First-Line Triple Therapy Does Not Improve the Eradication of Helicobacter pylori |
| title_fullStr | Adding Bismuth to Rabeprazole-Based First-Line Triple Therapy Does Not Improve the Eradication of Helicobacter pylori |
| title_full_unstemmed | Adding Bismuth to Rabeprazole-Based First-Line Triple Therapy Does Not Improve the Eradication of Helicobacter pylori |
| title_short | Adding Bismuth to Rabeprazole-Based First-Line Triple Therapy Does Not Improve the Eradication of Helicobacter pylori |
| title_sort | adding bismuth to rabeprazole based first line triple therapy does not improve the eradication of helicobacter pylori |
| url | http://dx.doi.org/10.1155/2017/5320180 |
| work_keys_str_mv | AT mengchiehwu addingbismuthtorabeprazolebasedfirstlinetripletherapydoesnotimprovetheeradicationofhelicobacterpylori AT yaokuangwang addingbismuthtorabeprazolebasedfirstlinetripletherapydoesnotimprovetheeradicationofhelicobacterpylori AT chungjungliu addingbismuthtorabeprazolebasedfirstlinetripletherapydoesnotimprovetheeradicationofhelicobacterpylori AT fangjungyu addingbismuthtorabeprazolebasedfirstlinetripletherapydoesnotimprovetheeradicationofhelicobacterpylori AT fuchenkuo addingbismuthtorabeprazolebasedfirstlinetripletherapydoesnotimprovetheeradicationofhelicobacterpylori AT minliliu addingbismuthtorabeprazolebasedfirstlinetripletherapydoesnotimprovetheeradicationofhelicobacterpylori AT chaohungkuo addingbismuthtorabeprazolebasedfirstlinetripletherapydoesnotimprovetheeradicationofhelicobacterpylori AT dengchyangwu addingbismuthtorabeprazolebasedfirstlinetripletherapydoesnotimprovetheeradicationofhelicobacterpylori AT yaokanghuang addingbismuthtorabeprazolebasedfirstlinetripletherapydoesnotimprovetheeradicationofhelicobacterpylori AT ichenwu addingbismuthtorabeprazolebasedfirstlinetripletherapydoesnotimprovetheeradicationofhelicobacterpylori |